Abstract
The appearance of protein aggregates is a common pathological hallmark that is associated with Alzheimer's disease and other major neurodegenerative disorders. Misfolded and damaged proteins that accumulate in neurodegenerative disease can be cleared through the ubiquitin proteasome system (UPS), a highly regulated pathway whose proper function is of paramount importance in the selective degradation of protein. Studies of the UPS have shown that alterations in the activity of this complex system may be contributors in the etiology of specific neurodegenerative disorders. Studies of familial genetic mutations and through experimental manipulation have suggested that a failure to clear toxic proteins through the UPS may exert important effect on the progression of these disorders; in addition, the accumulation of hallmark proteins themselves may in turn impair clearance by this pathway. This review will discuss recent observations indicating that alterations in the function and efficiency of the UPS are contributors in pathogenesis of Alzheimer’s disease, and discuss whether modulation of the UPS may be an appropriate therapeutic target in Alzheimer's disease and similar neurological disorders.
Keywords: Neurodegenerative diseases, ubiquitin proteasome system, Alzheimer’s disease, ubiquitin, protein degradation, amyloid, tau, ubiquitin-like proteins.
Current Enzyme Inhibition
Title:Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease
Volume: 9 Issue: 1
Author(s): Jason L. Eriksen
Affiliation:
Keywords: Neurodegenerative diseases, ubiquitin proteasome system, Alzheimer’s disease, ubiquitin, protein degradation, amyloid, tau, ubiquitin-like proteins.
Abstract: The appearance of protein aggregates is a common pathological hallmark that is associated with Alzheimer's disease and other major neurodegenerative disorders. Misfolded and damaged proteins that accumulate in neurodegenerative disease can be cleared through the ubiquitin proteasome system (UPS), a highly regulated pathway whose proper function is of paramount importance in the selective degradation of protein. Studies of the UPS have shown that alterations in the activity of this complex system may be contributors in the etiology of specific neurodegenerative disorders. Studies of familial genetic mutations and through experimental manipulation have suggested that a failure to clear toxic proteins through the UPS may exert important effect on the progression of these disorders; in addition, the accumulation of hallmark proteins themselves may in turn impair clearance by this pathway. This review will discuss recent observations indicating that alterations in the function and efficiency of the UPS are contributors in pathogenesis of Alzheimer’s disease, and discuss whether modulation of the UPS may be an appropriate therapeutic target in Alzheimer's disease and similar neurological disorders.
Export Options
About this article
Cite this article as:
L. Eriksen Jason, Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010007
DOI https://dx.doi.org/10.2174/1573408011309010007 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase-4 Modulation as a Potential Therapeutic for Cognitive Loss in Pathological and Non-Pathological Aging: Possibilities and Pitfalls
Current Pharmaceutical Design Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Subclinical Hypothyroidism and Cognitive Dysfunction in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets The Cholinergic System: An Emerging Drug Target for Schizophrenia
Current Pharmaceutical Design Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Atypical Neurotransmitters and the Neurobiology of Depression
CNS & Neurological Disorders - Drug Targets Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease
Current Proteomics Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)